August 11, 2022
The University of Cincinnati's Joseph Broderick, MD, provided comments in a TCTMD article reviewing the results of a recent study that found administering the drug tirofiban before endovascular thrombectomy does not improve functional outcomes in patients.
September 28, 2022
The University of Cincinnati's Alberto Espay, MD, was featured in an NBC News article reporting on results from a phase three Alzheimer's drug trial.
May 25, 2023
The University of Cincinnati's Rhonna Shatz, DO, was featured in an AARP article discussing ways to tell the difference between normal memory loss and more concerning memory problems.
March 6, 2023
The University of Cincinnati's Eva Mistry joined the Know Stroke Podcast to discuss the results of the BEST-II trial, her ongoing stroke research supported by PCORI, the success and advancement of mobile stroke units and more.
March 13, 2023
The University of Cincinnati's Rhonna Shatz, DO, provided expert commentary to Seasons and MSN about a recent study that found taking sleeping pills could raise the risk of Alzheimer's disease.
April 27, 2023
National outlets including U.S. News & World Report highlighted research presented by the University of Cincinnati's Alberto Espay on promising new treatments for Parkinson's disease.
May 9, 2023
The University of Cincinnati's Eva Mistry joined Fox 19's morning show to discuss American Stroke Month.
February 2, 2023
The University of Cincinnati's Joseph Broderick, MD, commented on a recent study that found adults genetically prone to poor oral health may be more likely to also show signs of declining brain health.
January 24, 2023
MedPage Today highlighted comments from a recent editorial written by the University of Cincinnati's Eva Mistry analyzing the results of a new study that found that using clot-busting drugs in stroke patients who had recently also been given blood thinners did not raise the risk of bleeding complications.
January 11, 2023
The University of Cincinnati's Alberto Espay, MD, spoke with NBC News about the impact of the cost of newly approved Alzheimer's drug Leqembi.